Experts React to RCT on Orforglipron for Weight Loss Maintenance

A randomized controlled trial published in Nature Medicine evaluates the efficacy of oral orforglipron for maintaining body weight reduction after initial loss achieved via injectable tirzepatide or semaglutide. Experts from the Science Media Centre highlight the study's clinical relevance, noting that switching to oral therapy helps participants maintain significantly more weight loss over 52 weeks compared to placebo. This addresses a major challenge in obesity care: weight regain after discontinuing injectable incretin therapies. Dr. Marie Spreckley from the University of Cambridge emphasizes that this offers a flexible alternative for patients seeking to avoid long-term injections due to convenience or cost. However, she notes limitations, including the one-year duration, lack of diversity in the US-based cohort, and absence of a group continuing injectable treatment for direct comparison. Spanish experts also praise the findings, stressing the importance of maintenance phases in treating obesity as a chronic disease. While gastrointestinal side effects were consistent with known profiles, longer-term studies are needed to assess durability. The research underscores the potential role of oral small-molecule GLP-1 receptor agonists in creating scalable, long-term obesity treatment pathways.